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Sphingosine 1-phosphate (S1P) is involved in a wide range of cellular processes, which 
include proliferation, apoptosis, lymphocyte egress, endothelial barrier function, angio-
genesis, and inflammation. S1P is produced by two isoenzymes, namely, sphingosine 
kinase 1 and 2 (SphK1 and 2) and once produced, S1P can act both in an autocrine and 
paracrine manner. S1P can be dephosphorylated back to sphingosine by two phospha-
tases (SGPP 1 and 2) or can be irreversibly cleaved by S1P lyase. S1P has a diverse 
range of functions, which is mediated in a receptor dependent, through G-protein cou-
pled receptors (S1PR1–5) or receptor independent manner, through intracellular targets 
such as HDACs and TRAF2. The involvement of S1P signaling has been confirmed 
in various disease conditions including lung diseases. The SphK inhibitors and S1PR 
modulators are currently under clinical trials for different pathophysiological conditions. 
There is a significant effort in targeting various components of S1P signaling for several 
diseases. This review focuses on the ways in which S1P signaling can be therapeutically 
targeted in lung disorders.
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inTRODUCTiOn
Sphingolipids are ubiquitous components of the cell membrane and provide structural integrity. 
Ceramide, one of the simplest structural sphingolipids, is converted to sphingosine which in turn 
is phosphorylated by two isoenzyme specific kinases, namely, SphK1 and 2 to form sphingosine 
1-phosphate (S1P) (1–3). There is a tight regulation of formation and degradation of S1P within 
the cells, through activation of SphKs to form S1P, dephosphorylation by phosphatases (SPPs) or 
degradation by S1P lyase (SPL) (Figure 1). Research over the past two decades identified S1P as 
a potent bioactive lipid molecule that regulates various cellular processes including cell growth, 
apoptosis, immune regulation, etc. (4–9).
SphK/S1P axis has been implicated in several diseases and is often considered as a potential 
therapeutic target. The level of expression of SphK1, and thereby S1P, has been found to correlate 
with the disease grade, severity, and patient survival. The involvement of sphingolipids varies from 
cardiovascular, cancer, inflammatory diseases to obesity.
Lung diseases are broadly classified into (a) airway diseases, where the airways, which carry 
oxygen and other gases, are affected; (b) lung tissue diseases, which mainly affect the architecture of 
lung; and (c) lung circulation/pulmonary diseases, which mainly affect the blood vessels in lungs. 
The involvement of S1P signaling in different types of lung diseases is currently an active area of 
research. We summarized the effects mediated by S1P signaling in lung diseases in the following 
sections.
FiGURe 1 | inside-out signaling of sphingosine 1-phosphate (S1P): SphK1 and SphK2 get activated by various ligands, in the cytoplasm and nucleus, 
respectively, and lead to the production of S1P. The schematic representation of the different fates of S1P is shown. S1P can be dephosphorylated to 
sphingosine by phosphatases (SGPP1/2) or irreversibly cleaved into hexadecenal and ethanolamine phosphate by S1P lyase. S1P, transported outside the cell by 
ABC transporters or Spns2, binds to any of the five G-protein-coupled receptors (S1PR1–5) on cell membrane. This activates several downstream signaling 
pathways. Besides this, S1P interacts with proteins such as TRAF2 in the cytoplasm and HDAC1/2 in the nucleus, thereby functioning as an intracellular second 
messenger.
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Asthma
The recent statistics provided by Global Asthma Network 
indicated that the number of people diagnosed with Asthma is 
increasing worldwide (10). The first study about the role of S1P 
was reported by Choi’s group using rat mast-cell line (RBL-2H3) 
and showed that crosslinking and stimulation of FcεRI (high-
affinity IgE receptor) could activate SphK1 and subsequently lead 
to S1P production (11). Conversely, high intracellular levels of 
sphingosine can block mast cell activation. Differential role of 
SphK1 and 2 has been observed in mast cells. Though both the 
isoforms are needed for production of TNF, SphK1 plays a key role 
in degranulation and migration towards antigen (12). S1P levels 
were increased in the airways of asthmatic patients but not in con-
trol subjects. Moreover, S1P also regulates the functions of airway 
smooth muscles during inflammation and airway remodeling 
(13). One of the mechanisms is through the inhibition of myosin 
phosphatase by S1P through a RhoA-dependent mechanism (14). 
Muscarinic receptor (MR) signaling that regulates airway resist-
ance has been implicated in asthma (15). The MR downstream 
signaling leads to constriction of peripheral airways, and the pro-
cess involves the activation of SphKs and release of intracellular 
Ca2+ levels (16). The systemic administration of S1P increased the 
airway resistance and cholinergic activity in whole mouse lung 
model (17). There was a marked increase on RANTES, CCR3, 
and IL-17 level after S1P treatment. Interestingly, S1P-mediated 
effects were abrogated by JTE-013 (an S1PR2 antagonist) or 
Y-27632 (an inhibitor of Rho kinase) indicating the role of S1PR2 
(18, 19). This was further confirmed by silencing of S1PR2 using 
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siRNA approach, which also showed the inhibition of S1P-driven 
Rho kinase activity. An inhibitor of SphK; SKI-II (4-[4-(4-chloro-
phenyl)-thiazol-2-ylamino]-phenol) was tested for its effect on 
bronchial smooth muscle hyperresponsiveness and airway 
inflammation. It was observed that the inhibitor augmented the 
hyperresponsiveness but had no effect on airway inflammation 
(20). An isoenzyme specific inhibitor of SphK1 (SK1-I) decreased 
airway hyperresponsiveness (AHR) and inflammation in a mast 
cell-dependent murine model of allergic asthma (21). SK1-I 
attenuated the antigen-dependent activation of both human and 
mouse mast cells and also reduced the circulating level of S1P in 
both lung and circulation. Further, NF-kB activation is a prereq-
uisite for the pro-inflammatory cytokine production after FcεRI 
activation. It was observed that SK1-I blocked the activation of 
p65 and reduced the phosphorylation of p65 at Ser276 position 
and was substantiated by the observation that TNF-alpha and 
IL-6 levels reduced after inhibitor treatment in ovalbumin chal-
lenged animals (21).
FTY720, an approved drug for multiple sclerosis, binds to 
all S1PRs except S1PR2 (22). Treatment with FTY720 sup-
pressed both Th1- and Th2-driven lung inflammation. Further, 
this agonist inhibited the ovalbumin-induced bronchial hyper 
reactivity to methacholine in mice and was associated with a 
decrease in the lymphocyte and eosinophil count in bronchiolar 
alveolar lavage (23). Idzko et al. also confirmed the observation 
and provided more mechanistic insight for the action of FTY720 
(24). The systemic administration resulted in an increase in the 
circulating dendritic cells along with an absence of lymphopenia 
and T cell retention in the lymph nodes. Studies were performed 
using isolated trachea from both mouse and rat where it was 
incubated with phospho-FTY720. The treatment increased the 
hyperresponsiveness to 5-hydroxytryptamine, and this effect was 
completely abolished in trachea isolated from S1PR3−/− mice 
indicating the role of S1PR3 in AHR (25). The involvement of 
a specific population of neurons, present in the vagal ganglia, 
in AHR was also analyzed. These ganglions express TRPV1 ion 
channel and intensify broncho constrictions very similar to that 
seen in asthma in sensitized lungs (26). Transcriptomic analysis 
of these cells revealed one of the abundant transcripts as S1PR3 
(26) and further confirmatory studies indicated that S1P is one of 
the signals involved in the cross talk between immune cell activity 
and neurons in asthmatic responses.
Infiltration of B cells is another hallmark of AHR after OVA sen-
sitization. The pretreatment of lungs with SphK inhibitors attenu-
ates the B cell mobilization, thereby linking S1P signaling to B cell 
recruitment. S1P-dependent AHR response is associated with an 
immune suppressive environment as seen from increased number of 
Treg cells. Monoclonal antibody-based depletion of CD20+ B cells 
in mice was associated with S1P-dependent AHR and inflammation. 
The recruitment of the B cells is a mechanism to counteract the S1P-
dependent inflammatory environment in lungs (27).
Of note, it was recently reported that ORM (yeast)-like protein 
isoform 3 (ORMDL3) gene is associated with asthma susceptibility, 
based on the genome-wide association studies (28). Interestingly, 
FTY720 reduced the ORMDL3 expression, AHR and associated 
inflammation, and mucus production and elevated the ceramide 
levels in house dust mite-induced lung inflammation model in 
mice, further confirming the potential beneficial role of FTY720 
in the treatment of asthma (29). Moreover, mice with increased 
expression of ORMDL were shown to have reduced levels of dif-
ferent types of sphingolipids (30).
Disodium cromoglycate (DSCG), a mast cell stabilizer, is 
used in the therapy of asthma and is included in British Thoracic 
Society guidelines. It was shown that DSCG inhibited asthma-
like features induced by S1P in mice as seen from the reduced 
recruitment of mast cells and B cells to lungs, decrease in AHR, 
and inflammation (31).
Lung Cancer
Lung cancer is one of the leading causes of cancer-related death 
worldwide. The role of SPL was investigated in the context of 
chemoresistance and the overexpression of this enzyme in A549 
cells makes it more sensitive to cisplatin, which was mediated 
through upregulation of p38 and JNK pathway (32). Beneficial 
effects of FTY720 in reducing tumor burden in a murine model 
of urethane-induced lung cancer were also reported (33). S1PR3 
expression was elevated in lung adenocarcinoma cell lines when 
compared to normal human airway epithelial cells. It was also 
noticed that signaling through S1PR3 increased the expression 
of EGFR and silencing of S1PR3 abolished the S1P-dependent 
EGFR activation (34). In non-small cell lung cancer (NSCLC) 
cells, the ectopic expression of Spns2, an S1P transporter, resulted 
in increased apoptosis through modulation of GSK-3β and Stat3 
pathways (35). A combination of ABC294640, an inhibitor of 
SphK2, and tumor necrosis factor-related apoptosis-inducing 
ligand (TRAIL) increased the apoptosis in NSCLC cell lines 
in  vitro (36). Silencing of Sphk2 showed similar effects with 
TRAIL, as shown by ABC294640 (36). Studies using fibroblasts 
showed that S1P in nucleus, produced mainly by SphK2, 
interacted with hTERT. Silencing either SphK2 or S1P binding 
pockets leads to decreased stability of hTERT and loss of telomere 
integrity (37). Genetical or pharmacological inhibition of SphK2 
decreased the growth of lung tumor in mice. This study demon-
strated the important role of S1P in maintaining telomere stability 
(37). Glucosylceramide synthase, in glycolipid biosynthesis, was 
shown to be over expressed in lung cancer and is implicated in 
chemoresistance (38). Inhibition of this enzyme enhanced the 
anticancer potential of ABC294640 in lung cancer (39). This 
study advocates the possibility of a combination of SphK2 inhibi-
tors and GCS inhibitors in lung cancer treatment.
Mesothelioma is a resistant form of cancer, which primarily 
develops in the lining of the lungs. Sphingosine inhibited the 
growth of mesothelioma cell lines and induced cell cycle arrest 
at the G0/G1 through the inhibition of PKC-δ (40). The elevated 
expression of SphK1 in malignant pleural mesothelioma tumor 
samples and cell lines has been reported. There is upregulation of 
histone acetyl transferases and a decrease in the expression of cell 
cycle-dependent kinase inhibitor genes (41). In a mouse model 
of this disease, the granulomatous inflammation (which was 
considered as a nearly mesothelioma like symptom) was greatly 
attenuated in SphK1−/− mice as compared to SphK1+/+ mice (41) 
indicating the possibility of targeting SphK1 for the treatment of 
mesothelioma. However, this study does not exclude the role of 
SphK2 in mesothelioma, which requires further investigations.
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Pulmonary Hypertension (PH)
The role of sphingolipids in PH is also being identified. SphK1 
and S1P were elevated in lungs of patients with PH as well as 
in animal models of hypoxia-mediated pulmonary hypertension 
(HPH). There is an increased proliferation of pulmonary artery 
smooth muscle cells (PASMCs), and associated pulmonary 
vascular remodeling is observed during PAH. Elevated levels of 
S1P has been detected in the plasma of PAH patients (42). The 
SphK1−/− mice were protected against HPH as seen from reduced 
right ventricular systolic pressure and less severe pulmonary 
vascular remodeling (43). Interestingly, there was no protective 
effect in SphK2−/− against HPH indicating the beneficial role of 
SphK 1 inhibition in the treatment of PH (43). S1P promoted the 
PASMCs proliferation (44, 45) through S1PR2, and this effect was 
nullified in SphK1−/− mice. The involvement of S1PR2 was further 
confirmed by employing JTE-012, which prevented HPH and 
vascular remodeling (44). The treatment of rats suffering from the 
late stage of PAH with SphK1 attenuated the disease severity and 
reduced the levels of circulating S1P (45). The macrophages have 
a tendency to accumulate near lung arterioles and express high 
levels of leukotriene B4 (LTB4), which triggers cell death in pul-
monary artery endothelial cells. This effect was mediated through 
inhibition of SphK1–eNOS signaling (44). The blocking of LTB4 
production reversed fulminant PH through the restoration of the 
SphK1–eNOS pathway. Hypoxic pulmonary vasoconstriction 
(HPV) is also a contributing factor for PH. Recently, the role of 
cystic fibrosis transmembrane regulator (CFTR) is highlighted in 
HPV. It was observed that neutral sphingomyelinase and hypoxia-
induced pulmonary vasoconstriction were inhibited by genetic 
or pharmacological silencing of SphK1 or through antagonism 
of S1PR 2 and 4 (45). These studies effectively pointed out the 
importance of S1P signaling in PH and can be the molecular 
target in the treatment of PH.
Cystic Fibrosis (CF)
Cystic fibrosis is a multisystem genetic disorder, which mainly 
affects the lungs. The study by Xu et  al. (46) showed that the 
functionally impaired lung dendritic cells contribute to the devel-
opment of CF. The decreased level of S1P in the BALF results in a 
reduced recruitment of dendritic cells to the lungs and also affects 
the activation. The exogenous addition of S1P or FTY720 to the 
CF BALF could restore the expression of MHCII and CD40. This 
effect seems to be mediated through S1PR as the addition of 
JTE-013 and VPC20319 (an S1PR1/3 agonist) brought down the 
expression of the activation markers. The dysfunction of CFTR 
alters immune cell responses, and CFTR is involved in cellular 
uptake of S1P. The reduced expression of CFTR in CF will lead to 
a reduced uptake of S1P. Thus, S1P would be available to bring in 
an exacerbated cycle of inflammation and angiogenesis as seen 
in CF (47). S1P inhibits the CFTR activity through AMPK (48) 
and controls its own degradation through CFTR conductance 
modulation that depends on AMPK and S1PR2. The expres-
sion of a mutated form of CFTR (ΔF508) is observed in a vast 
majority of CF patients and leads to an increased sphingolipid 
synthesis, which indicated that CFTR functions as a feedback 
system in sphingolipid biosynthesis (49). The level of S1P was 
found to be reduced in a mutant form of CFTR mouse. However, 
treatment with SPL inhibitor (LX2931) could restore the S1P 
levels. Moreover, the CF phenotype of CFTR mutant mice was 
partially corrected by LX2931 further confirming the possible 
therapeutic targeting of S1P signaling in CF (50).
Pulmonary Fibrosis (PF)
Pulmonary fibrosis thickens the alveoli leading to the develop-
ment of scars and is associated with severe breathing problems. 
SPL is reported to be an endogenous inhibitor of pulmonary 
fibrosis (51). The expression levels of SphK1 and SphK2 were 
found to be high in idiopathic pulmonary fibrosis patients, and 
the level of expression correlated with the severity of the disease. 
The knockdown of SphK1 protected mice from lung fibrogenesis. 
The levels of S1P and dihydro S1P were high in mice challenged 
with bleomycin. Administration of SK-II reduced the levels of the 
sphingolipids and protected against the disease and the disease 
associated mortality (52). A similar effect was seen in radiation-
induced pulmonary fibrosis, where treatment with myriocin 
reduced the S1P and dihydro S1P levels, thereby reducing the 
onset of the disease (53). The EMT that is associated with PF 
has an increased level of S1P associated with it. S1P-mediated 
EMT through interaction with S1PR2 and S1PR3 and activates 
p-Smad3, RhoA-GTP, and TGF-β (54).
Acute Lung injury (ALi) or Acute 
Respiratory Distress Syndrome (ARDS)
Acute lung injury/acute respiratory distress syndrome is an acute 
respiratory failure associated with substantial morbidity and 
mortality to patients (55). Loss of Forkhead protein (FOXF1) in 
endothelial cells leads to ALI and administration of S1P reduced 
the lung edema and promoted survival (56). Further, knockdown 
of FOXF1 leads to increased expression of S1PR1 and thereby 
maintain the endothelial barrier integrity (56). Genetic screening 
of ALI subjects found a striking link between a single nucleotide 
polymorphism in cortactin gene and ALI. Cortactin is involved in 
maintaining barrier integrity. Interestingly, this polymorphism in 
cortactin was responsible for diminishing the barrier protective 
effects of S1P in endothelial cells making them more susceptible to 
ALI (57). SphK1 also afford protection against radiation-induced 
lung injury (RILI). SphK1−/− mice were highly susceptible to RILI 
and S1P receptor agonists like FTY720, p-FTY720, and SEW2871 
attenuated RILI (58).
Glucocorticoids are currently in trials for ALI. Treatment 
with glucocorticoids leads to the enhanced synthesis of SphK1 
and S1P production. Conversely, silencing SphK1 expression 
attenuated the effects of glucocorticoids in ALI. SphK1−/− mice 
were more susceptible for LPS induced vascular leakage and 
were associated with delayed clearance of histamine and poor 
recovery from anaphylaxis, and these adverse events were 
reversed by administering exogenous S1P (59). The role of 
S1PR2 has been investigated in mast cell-dependent passive 
systemic anaphylaxis and found that pharmacological or genetic 
silencing of S1PR2 reduced the antigen-induced lung perivascu-
lar edema and anaphylactic responses. Mast cells increased the 
T cell recruitment through S1PR2 signaling coupled to STAT3 
pathway. This, in turn, leads to production of chemokines in 
acute pulmonary allergic responses. Studies using antibody 
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TABLe 1 | Sphingosine 1-phosphate (S1P) signaling in lung disorders: the effects of different inhibitors of SphKs, S1P receptor modulators, and S1P 
antibody in different diseases related to lung with possible mechanism of action.
S. no. Drug used Disease Model Mechanism of action Reference
1 JTE-013 Asthma Human bronchial smooth muscle 
(BSM) cells
Suppression of S1P-induced inhibition of RANTES 
production
(18)
2 JTE-013 Asthma Mouse model of allergic airway 
inflammation
Inhibition of S1P-mediated BSM contraction (19)
3 SKI-II Asthma Ovalbumin-sensitized mouse 
model
Alleviation of BSM hyperresponsiveness (20)
4 Inhibitor of 
SphK1
Asthma Mast cell-dependent mouse model 
of ovalbumin-induced asthma
Inhibition of antigen-dependent mast cell activation and 
NF-κB activation
(21)
5 FTY720 Asthma Antigen-sensitized murine asthma 
model
Inhibition of Th1- and Th2-mediated airway inflammation, 
inhibition of T cell, and eosinophil infiltration into bronchial 
tissue
(23)
6 FTY720, S1P Asthma Mouse asthma model Suppression of Th2-dependent eosinophilic airway 
inflammation and bronchial hyperresponsiveness
(24)
7 SphKI/II 
inhibitor
Asthma OVA-sensitized BALB/c mice Inhibits phosphorylation of sphingosine and reduced B cell 
infiltration into lungs
(28)
8 FTY 720 Asthma House dust mite model of allergic 
lung inflammation in C57BL/6J 
mice
Attenuates ORMDL3 expression (29)
9 FTY 720 Lung cancer Urethane-induced lung cancer in 
BALB/c mice
Decreased PCNA, increased caspase expression, and 
impaired tumor development
(33)
10 ABC294640 Lung cancer Non-small cell lung cancer cell 
lines
Augmentation of antitumor effect of tumor necrosis factor-
related apoptosis-inducing ligand and upregulation of death 
receptor expression
(36)
11 ABC294640 Lung cancer A549 xenografts in SCID mice Reduced hTERT expression (37)
12 Sphingosine Mesothelioma Mesothelioma cell lines Inhibition of PKC-δ and induction of cell cycle arrest (40)
13 JTE-013 Pulmonary 
hypertension (PH)
Hypoxia-mediated PH model Prevention of development of hypoxia-mediated pulmonary 
hypertension
(42)
14 SKI2 PH Hypoxia-mediated PH model in 
rodents
Reduced right ventricular systolic pressure, right ventricular 
hypertrophy, and pulmonary remodeling
(42)
15 SKI-II PH Pulmonary arterial smooth muscle 
cells
Attenuation of hypoxia-induced increase in pulmonary arterial 
pressure
(45)
16 JTE-013 Hypoxic pulmonary 
vasoconstriction
Perfused murine lungs Reduction in pulmonary arterial pressure (45)
17 JTE-013 Cystic fibrosis (CF) Lung dendritic cells Reduced expression of MHCII and CD40 (46)
18 VPC23019 CF Lung dendritic cells Reduced expression of MHCII and CD40 (46)
19 LX2931 CF Cystic fibrosis transmembrane 
regulator mutant mice
Increases level of S1P, normalization of the MoDC/cDC 
ratio, reduction in T and B cells, and normalization of pro-
inflammatory cytokine levels
(50)
21 Myriocin PF Mouse model of radiation-induced 
pulmonary fibrosis
Blocks sphingolipid de novo biosynthesis and reduced level 
of SphK1 and serine palmitoyl transferase
(53)
22 S1P Acute lung injury 
(ALI)
Conditional FOXF1 knock out mice 
model
Restored endothelial barrier function and decreased lung 
edema
(56)
23 SEW2781 ALI LPS induced vascular leakage Reduced vascular leakage and strengthening of endothelial 
barrier
(59)
24 Sphingomab Anaphylaxis Antigen-induced allergic response 
murine model
Inhibition of mast cell activation and reduction in histamines, 
cytokines, and chemokines
(60)
25 JTE-013 Anaphylaxis Antigen-induced allergic response 
murine model
Inhibition of mast cell activation and reduction in histamines, 
cytokines, and chemokines
(60)
26 CYM-5442, 
RP-002, 
AAL-R
Influenza C57BL/6 mice infected with 
influenza virus
Reduction in cytokine and chemokine production, inhibition 
of macrophage, and natural killer cell accumulation in lungs
(66)
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against S1P and S1PR2 agonists demonstrated that chemokine 
secretion and recruitment of T  cells were reduced, further 
confirming the role of S1PR2 (60). Cui et al. reported another 
mechanism for S1PR2 where it inhibited the signaling through 
Akt, eNOS, and nitric oxide production and protected the 
animals from anaphylactic shock (61).
Chronic Obstructive Pulmonary 
Disease (COPD)
Chronic obstructive pulmonary disease is an umbrella term refer-
ring to chronic pathological conditions affecting the respiratory 
system (62). Cordts et al. reported the mRNA expression profil-
ing of S1PRs in the lungs of COPD patients showed significant 
decrease in S1PR5 and proposed that this receptor can be a novel 
target for pharmacotherapy (63). mRNA expression profiles of 
different SphKs, S1PRs, SPL, and phosphatase were analyzed in 
COPD patients and found significant upregulation of SphKs, 
S1PR2, and S1PR5 (63). The role of S1P signaling in efferocy-
tosis was also reported. Cigarette smoke-inhibited efferocytosis 
was significantly reversed by either S1P or FTY720 (64). These 
observations further support the notion that S1P pathway can be 
a potential therapeutic target in COPD.
influenza
Influenza viruses are seasonal human pathogens causing 
pandemic morbidity and mortality. S1P-signaling components 
have been shown to interfere with virus infection and replica-
tion. SPL overexpressing cells were found to be resistant for 
viral amplification as compared to vector transfected cells 
as evident from reduced viral titer. The SPL overexpression 
leads to rapid activation of both STAT1 and ERK pathways 
(65). Teijaro et  al. reported that during influenza infections, 
S1PR1 agonism was effective in suppressing pro-inflammatory 
cytokine and chemokine production as well as innate immune 
cell recruitment (66). S1PR1 located mainly in the pulmonary 
endothelial cells and agonists such as CYM-5442, RP-002, and 
AAL-R (67) were effective in protecting the mice from lethal 
infection with influenza virus. Using a Ferret model of human 
2009 pandemic influenza virus infection, it was observed that 
the S1PR1 agonist RP-002 was effective in alleviating clinical 
symptoms and lung pathology independent of virus replica-
tion. Importantly, a combination of RP-002 and oseltamivir 
(an antiviral drug) was more effective in blunting immune 
response and suppressing viral replication (68). Thus, this 
study provided the advantages of combining antiviral drugs 
and S1PR1 modulators in the treatment of influenza infection. 
The various effects mediated by S1P system in different lung 
disorders are summarized in Table 1.
COnCLUSiOn
Sphingolipids are known to be involved in the development 
and progression of diseases. The level of SphK1 and S1P is 
elevated and often correlates with the disease severity. The 
abrogation of the enzyme and its product was found to lead 
to a reduction in the disease symptoms. The review thus sum-
marizes the effects mediated by the SphK/S1P axis and stresses 
the importance of developing therapies targeting the signaling 
of sphingolipids, and hence the effective treatment of several 
pulmonary diseases.
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